SUMOylation of Enzymes and Ion Channels in Sensory Neurons Protects against Metabolic Dysfunction, Neuropathy, and Sensory Loss in Diabetes.


Journal

Neuron
ISSN: 1097-4199
Titre abrégé: Neuron
Pays: United States
ID NLM: 8809320

Informations de publication

Date de publication:
23 09 2020
Historique:
received: 23 11 2019
revised: 20 04 2020
accepted: 26 06 2020
pubmed: 1 8 2020
medline: 21 11 2020
entrez: 1 8 2020
Statut: ppublish

Résumé

Diabetic peripheral neuropathy (DPN) is a highly frequent and debilitating clinical complication of diabetes that lacks therapies. Cellular oxidative stress regulates post-translational modifications, including SUMOylation. Here, using unbiased screens, we identified key enzymes in metabolic pathways and ion channels as novel molecular targets of SUMOylation that critically regulated their activity. Sensory neurons of diabetic patients and diabetic mice demonstrated changes in the SUMOylation status of metabolic enzymes and ion channels. In support of this, profound metabolic dysfunction, accelerated neuropathology, and sensory loss were observed in diabetic gene-targeted mice selectively lacking the ability to SUMOylate proteins in peripheral sensory neurons. TRPV1 function was impaired by diabetes-induced de-SUMOylation as well as by metabolic imbalance elicited by de-SUMOylation of metabolic enzymes, facilitating diabetic sensory loss. Our results unexpectedly uncover an endogenous post-translational mechanism regulating diabetic neuropathy in patients and mouse models that protects against metabolic dysfunction, nerve damage, and altered sensory perception.

Identifiants

pubmed: 32735781
pii: S0896-6273(20)30491-8
doi: 10.1016/j.neuron.2020.06.037
pii:
doi:

Substances chimiques

TRPV Cation Channels 0
TRPV1 protein, mouse 0
Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) EC 1.2.1.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1141-1159.e7

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no competing interests.

Auteurs

Nitin Agarwal (N)

Pharmacology Institute, Heidelberg University, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany.

Francisco J Taberner (FJ)

Pharmacology Institute, Heidelberg University, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany.

Daniel Rangel Rojas (D)

Pharmacology Institute, Heidelberg University, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany.

Mirko Moroni (M)

Molecular Physiology of Somatic Sensation, Department of Neuroscience, Max-Delbrück Centre for Molecular Medicine, Robert-Rössle Straße 10, 13092 Berlin, Germany.

Damir Omberbasic (D)

Molecular Physiology of Somatic Sensation, Department of Neuroscience, Max-Delbrück Centre for Molecular Medicine, Robert-Rössle Straße 10, 13092 Berlin, Germany.

Christian Njoo (C)

Pharmacology Institute, Heidelberg University, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany.

Alexandra Andrieux (A)

Nuclear Organization and Oncogenesis Unit, INSERM U993, Institute Pasteur, 75015 Paris, France.

Pooja Gupta (P)

Pharmacology Institute, Heidelberg University, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany.

Kiran K Bali (KK)

Pharmacology Institute, Heidelberg University, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany.

Esther Herpel (E)

Institute of Pathology, Heidelberg University, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.

Faramarz Faghihi (F)

Pharmacology Institute, Heidelberg University, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany.

Thomas Fleming (T)

Medical Clinic Heidelberg, Department of Medicine I and Clinical Chemistry, University Hospital of Heidelberg, Heidelberg University, INF 410, 69120 Heidelberg, Germany.

Anne Dejean (A)

Nuclear Organization and Oncogenesis Unit, INSERM U993, Institute Pasteur, 75015 Paris, France.

Stefan G Lechner (SG)

Pharmacology Institute, Heidelberg University, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany.

Peter P Nawroth (PP)

Medical Clinic Heidelberg, Department of Medicine I and Clinical Chemistry, University Hospital of Heidelberg, Heidelberg University, INF 410, 69120 Heidelberg, Germany.

Gary R Lewin (GR)

Molecular Physiology of Somatic Sensation, Department of Neuroscience, Max-Delbrück Centre for Molecular Medicine, Robert-Rössle Straße 10, 13092 Berlin, Germany.

Rohini Kuner (R)

Pharmacology Institute, Heidelberg University, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany. Electronic address: rohini.kuner@pharma.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH